
FIG.1



\\Picasso\SHARE\507\Jill\Results\Jill-May-Aug 2002\310502-Concen-3B\Glu-C-2hr (18:16 04/04/05)






FIG.2



\\Picasso\SHARE\507\JiII\\Results\JiII-May-Aug 2002\310502-Concen-3B\TRP-2hr (18:16 04/04/05)



WO 2005/097822 PCT/CA2005/000547

### 3/10

-	MINTERPRETATION	ETDEZCIETETE				
∸.	MKAKEKIÖHT	WRWGWKWGTM	LLGILMIÇSA	TEKLWVTVYY	GVPVWKEATT	TLFCASDAKA
61	TDIEAUMANA	THACALTDEN	POEVVLVNVT	ENFNMWKNDM	VEOMHEDITS	TATOOST ROCK
121	KTIPLCVSLK	CTDLGNATNT	NSSNTNSSSG	EMMMEKGETK	NCSFNTSTST	PCKTIOKEVAE
181	EAKPDITEID	NOTTSVTITS	CNTSVITOAC	PKVSFEPTPT	HYCADAGEAT	T. WONTATIVITIENTO
241	TGPCTMASTA	QCTHGIRPVV	STOLLLNGSL	AFFEVVIRSA	METDMAKTT	TATE OF THE TATE
301	CTRPNNNTRK	SIRIQRGPGR	AFVTIGKTGN	MROAHCNIER	AKWINATI.KOT	A CET DECECN
36 I	NKTITIFKÖSS	GGDPEIVTHS ·	FNCGGEFFYC	NSTOLENSTW	FNSTWSTEGS	MMTTECCTOTTO
421	PECKIKGEIN	MWQEVGKAMY.	APPISGOTRC	SSNTTGTTTT	RDGGNNNNGS	EIFRPGGGDM
481	RDNWRSELYK	YKVVKIEPLG	VAPTKAKRRV	VOREKR		

#### Figure 3.

1 '	IPGEKLWVTV	YYGVPVWKEA	TTTLFCASDA	KAYDTEVHNV	WATTHACTOTTO	PDPQEVELVŃ
61	ATEMENMMKN	NMVEQMHEDI	ISLWDOSLKP	CVKLTPLCVT	TATOTOT DATE	ATTIATATOTICS ATATAT
14.	T SNSEGIIKGG	EMKNCSFNIT	TSIGDKMOKE	VAT.T.VRT.DTW	CTDMDcmcvn	TTOOMGTTT
то.	I QACPKISFEP	TETHACTED	FAILKCNDKK	FSGKGSCKNW	STVOCTEGTD	DVVVCTIOT T T AT
24.	r Gonwerd AT	RSENFIDNAK	TIIVHLNESV		KDKDTUTCDC	ひろ だなののガンスナナー
્ ૩૫.	r GITROAHCNI	SRAKWNDTLR	OIVSKLKEOF	KNKTTVFTOS	SCICIDARTIME	CENTOCOMBA
20.	r CMISETEMSI.	MNGNNTWNNT	TGSNNNTTLO	CKTKOTTNIMM	ORTHURNATURE	DETCOTEGG
#4.	r wirgninikn	GGKDTDTDDT	EIFRPGGGDM	RDNWRSELYK	YKVVTIEPLG	VAPTKAKRRV
48.	L VOREKR					

#### Figure 4.




Figure 5:




Figure 6.

Ig61b12 neutralizing specificities

Strain	Sequence	Clade	Clade Neutralizing
Consensus	LWVTVYYGVPVWKEATTTLFCASDAK	1	Titer (ID50)
Uq273	LWVTVYYGVPVWRDAETTLECASDAK	4	10 µg/ml
DJ258	LWVTVYYGVPVWRDAETTLFCASDAK	⋖	35
Z V	LWVTVYYGVPVWKEATTTLFCASDAK	<b>&amp;</b>	<b>*0.04</b>
Lai (IIIB)	LWVTVYYGVPVWKEATTTLFCASDAK	<b>&amp;</b>	<b>*0.04</b>
BK132	LWVTVYYGVPVWKEATTTLFCASDAK	മ	9.3
SF2	LWVTVYYGVPVWKEATTTLFCASDAK	മ	0.2
DJ259	LWVTVYYGVPVWKDANPPLFCASDAK	S S	29
ZM20	LWVTVYYGVPVWKEAKTTLFCASDAK	v	>50
CM235	LWVTVYYGVPVWRDADTTLFCASDAK	W.	20
BZ163	LWVTVYYGVPVWKDATTTLFCASDAK	· <b>L</b>	49
MVP5180	LWVTVYYGVPVWEEAAPVLFCASDAN	0	>50

Figure 7





Figure 8.






Figure 9.




Figure 10.

FIG. 11

# Peptide binding to IgG1 b12





FIG. 12

## Inhibition of IgG1 b12 binding to peptide by gp120



WO 2005/097822 PCT/CA2005/000547

10/10

A

gp120 Recognition by Differentially Immunized Mice




Figure 13A

В

N terminal Peptide Recognition by Differentially Immunized Mice




Figure 13B

С

Scrambled Peptide Recognition by Differentially Immunized Mice




Figure 13C